Brought to you by 
ProGenTech closes its $21mm Series C venture round
13 May 2008
Executive Summary
ProGenTech (developing nucleic acid purification systems) has raised $21mm through the closing of its Series C venture round. New investors Bay City Capital and DT Capital led the financing.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com